Actively Recruiting
Single-cell Sequencing of BLF to Guide the Treatment of Radiation Pneumonitis or Immune Checkpoint Inhibitor Pneumonitis
Led by Xinqiao Hospital of Chongqing · Updated on 2025-07-14
40
Participants Needed
1
Research Sites
126 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A multicenter, exploratory clinical research, to map the radiation or immune checkpoint inhibitor pneumonitis in patients with alveolar lavage single-celled map. Find out the pathogenesis and prevention strategies of radiation or immune checkpoint inhibitor pneumonitis. Specific treatment is given based on the recommendation of the treatment guidelines for radiation or immune checkpoint inhibitor pneumonitis and the results of single cell sequencing, which will become a new technology for clinical application.
CONDITIONS
Official Title
Single-cell Sequencing of BLF to Guide the Treatment of Radiation Pneumonitis or Immune Checkpoint Inhibitor Pneumonitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent and able to follow the study protocol
- Diagnosed with radiation pneumonitis or immune checkpoint inhibitor pneumonitis after radiotherapy or immunotherapy for non-small cell lung cancer, without prior glucocorticoid or other drug treatment
- Age between 18 and 75 years
- Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 to 3
- No contraindications to bronchoalveolar lavage
You will not qualify if you...
- Poor compliance or violation of study rules
- Liver or kidney dysfunction such as myocardial infarction, angina, or significantly elevated liver enzymes
- Use of corticosteroids or immunosuppressive drugs within 14 days before enrollment
- Severe infection or hospitalization due to infection within 4 weeks before enrollment
- Active or severe chronic infections requiring systemic antibiotics within 14 days before enrollment
- Untreated chronic hepatitis B, high HBV DNA levels, or active hepatitis C infection
- Known HIV infection
- Participation in another clinical trial or use of investigational drugs within 28 days before enrollment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Xinqiao Hospital
Chongqing, Chongqing Municipality, China, 400037
Actively Recruiting
Research Team
J
Jianguo Sun, doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here